Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot73710.32687/0869-866X-2021-29-s2-1304-1310Научная статьяNEUROLOGICAL COMPLICATIONS OF COVID-19: REVIEW OF LITERATURE AND OWN EXPERIENCEPrikazchikovS. V.-GeneralovV. O.-SadykovT. R.veeg.russia@gmail.comMamedovL. A.-Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentCenter of diagnostics and treatment for epilepsy «PlanetaMed»1512202129S21304131023112021Copyright © 2021,2021According to the literature, the main neurological complications of COVID-19 are hyposmia, hypogeia, headache, dizziness, myalgia, and severe neurological syndromes like encephalopathy, stroke, and coma. The mechanisms of neurological complications of the acute period are direct viral damage, hypoxic damage, and immune damage due to the activation of inflammation, including autoantibodies. After the end of the acute phase of the disease, neurological complications in the form of asthenic syndrome, vascular syndrome, exacerbation of chronic diseases (deterioration of cognitive and communication functions in patients with autism, schizophrenia, exacerbation of autoimmune neurological diseases, aggravation of the condition of patients with tics, increased frequency of epileptic seizures in adults and children, resumption of epileptic seizures in patients who were previously in stable remission, the debut of epileptic seizures). These disorders are based on the following mechanisms: neuroinflammation, activation of pro-inflammatory cytokines (IL-1, -2, -6, -8, -10, -17, -18, CXCL10, CCL2), formation of autoantibodies, increased permeability of the blood-brain barrier, mitochondrial dysfunction, adrenal and thyroid dysfunction, venous dyscirculation. In the treatment of neurological complications after a COVID-19 infection, it is advisable to use anti-inflammatory therapy, mitochondrial therapy (including the technique of intermittent hypoxic-hyperoxic therapy), detoxication, correction of hormonal status (primarily the state of the adrenal glands and thyroid gland), vasoactive therapy, and symptomatic therapy.COVID-19COVID-19reviewcomplicationsmitochondriaepilepsyautismобзоросложнениямитохондрииэпилепсияаутизм1.Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia // J. Thromb. Haemost. 2020. Vol. 18, N 4. P. 844-847. DOI: 10.1111/jth.14768.2.Herman C., Mayer K., Sarwal A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19 // Neurology. 2020. Vol. 95, N 2. P. 77-84. DOI: 10.1212/WNL.0000000000009673.3.Ellul M. A., Benjamin L., Singh B. et al. Neurological associations of COVID-19 // Lancet Neurol. 2020. Vol. 19, N 9. P. 767-783. DOI: 10.1016/S1474-4422(20)30221-0.4.The Lancet Neurology. The neurological impact of COVID-19 // Lancet Neurol. 2020. Vol. 19, N 6. P. 471. DOI: 10.1016/S1474-4422(20)30142-3.5.Helms J., Kremer S., Merdji H. et al. Neurologic features in severe SARS-CoV-2 infection // N. Engl. J. Med. 2020. Vol. 382, N 23. P. 2268-2270. DOI: 10.1056/NEJMc2008597.6.Chou S. H., Beghi E., Helbok R. et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19- a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium // JAMA Netw. Open. 2021. Vol. 4, N 5. P. e2112131. DOI: 10.1001/jamanetworkopen.2021.12131.7.Maury A., Lyoubi A., Peiffer-Smadja N. et al. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians // Rev. Neurol. (Paris). 2021. Vol. 177, N 1-2. P. 51-64. DOI: 10.1016/j.neurol.2020.10.001.8.Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China // JAMA Neurol. 2020. Vol. 77, N 6. P. 683-690. DOI: 10.1001/jamaneurol.2020.1127.9.Ahmad I., Rathore F. A. Neurological manifestations and complications of COVID-19: A literature review // J. Clin. Neurosci. 2020. Vol. 77. P. 8-12. DOI: 10.1016/j.jocn.2020.05.017.10.Wu Y., Xu X., Chen Z. et al. Nervous system involvement after infection with COVID-19 and other coronaviruses // Brain Behav. Immun. 2020. Vol. 87. P. 18-22. DOI: 10.1016/j.bbi.2020.03.031.11.Delgado-Roche L., Mesta F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection // Arch. Med. Res. 2020. Vol. 51, N 5. P. 384-387. DOI: 10.1016/j.arcmed.2020.04.019.12.Edeas M., Saleh J., Peyssonnaux C. Iron: innocent bystander or vicious culprit in COVID-19 pathogenesis? // Int. J. Infect. Dis. 2020. Vol. 97. P. 303-305. DOI: 10.1016/j.ijid.2020.05.110.13.Skalny A. V., Rink L., Ajsuvakova O. P. et al. Zinc and respiratory tract infections: perspectives for COVID-19 (review) // Int. J. Mol. Med. 2020. Vol. 46, N 1. P. 17-26. DOI: 10.3892/ijmm.2020.4575.14.Saleh J., Peyssonnaux C., Singh K. K., Edeas M. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis // Mitochondrion. 2020. Vol. 54. P. 1-7. DOI: 10.1016/j.mito.2020.06.008.15.Bellastella G., Maiorino M. I., Esposito K. Endocrine complications of COVID-19: what happens to the thyroid and adrenal glands? // J. Endocrinol. Invest. 2020. Vol. 43, N 8. P. 1169-1170. DOI: 10.1007/s40618-020-01311-8.16.Akbas E. M., Akbas N. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency // Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2021. Vol. 165, N 1. P. 1-7. 10.5507/bp.2021.01110.5507/bp.2021.011.17.Трошина Е. А., Мельниченко Г. А., Сенюшкина Е. С., Мокрышева Н. Г. Адаптация гипоталамо-гипофизарно-тиреоидной и гипоталамо-гипофизарно-надпочечниковой систем к новому инфекционному заболеванию - COVID-19 в условиях развития COVID-19-пневмонии и/или цитокинового шторма // Клиническая и экспериментальная тиреоидология. 2020. Т. 16, № 1. С. 21-27. DOI: https://doi.org/10.14341/ket1246118.Zhang J., Tecson K. M., McCullough P. A. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy // Rev. Cardiovasc. Med. 2020. Vol. 21, N 3. P. 315-319. DOI: 10.31083/j.rcm.2020.03.126.19.Hannemann J., Balfanz P., Schwedhelm E. et al. Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients // Sci. Rep. 2021. Vol. 11. P. 9895. DOI: 10.1038/s41598-021-89180-w.20.St-Jean J. R., Jacomy H., Desforges M. et al. Human respiratory coronavirus OC43: genetic stability and neuroinvasion // J. Virol. 2004. Vol. 78, N 16. P. 8824-8834. DOI: 10.1128/JVI.78.16.8824-8834.2004.21.Bobker S. M., Robbins M. S. COVID-19 and headache: a primer for trainees // Headache. 2020. Vol. 60, N 8. P. 1806-1811. DOI: 10.1111/head.13884.22.Sampaio Rocha-Filho P. A., Voss L. Persistent headache and persistent anosmia associated with COVID-19 // Headache. 2020. Vol. 60, N 8. P. 1797-1799. DOI: 10.1111/head.13941.23.Saad M. A., Alfishawy M., Nassar M. et al. COVID-19 and autoimmune diseases: a systematic review of reported cases // Curr. Rheumatol. Rev. 2021. Vol. 17, N 2. P. 193-204. DOI: 10.2174/1573397116666201029155856.24.Liu Y., Sawalha A. H., Lu Q. COVID-19 and autoimmune diseases // Curr. Opin. Rheumatol. 2021. Vol. 33, N 2. P. 155-162. DOI: 10.1097/BOR.0000000000000776.25.Colizzi M., Sironi E., Antonini F. et al. Psychosocial and behavioral impact of COVID-19 in autism spectrum disorder: an online parent survey // Brain Sci. 2020. Vol. 10, N 6. P. 341. DOI: 10.3390/brainsci1006034126.Mares J., Hartung H. P. Multiple sclerosis and COVID-19. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc // Czech. Repub. 2020. Vol. 164, N 3. P. 217-225. DOI: 10.5507/bp.2020.033.27.Fonseca L., Diniz E., Mendonça G. et al. Schizophrenia and COVID-19: risks and recommendations // Braz. J. Psychiatry. 2020. Vol. 42, N 3. P. 236-238. DOI: 10.1590/1516-4446-2020-0010.28.Tufan A., Avanoğlu Güler A., Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs // Turk. J. Med. Sci. 2020. Vol. 50, N SI-1. P. 620-632. DOI: 10.3906/sag-2004-168.29.Galic M. A., Riazi K., Pittman Q. J. Cytokines and brain excitability-// Front. Neuroendocrinol. 2012. Vol. 33, N 1. P. 116-125. DOI: 10.1016/j.yfrne.2011.12.002.30.Levin S. G., Godukhin O. V. Modulating effect of cytokines on mechanisms of synaptic plasticity in the brain // Biochemistry (Mosc.). 2017. Vol. 82, N 3. P. 264-274. DOI: 10.1134/S000629791703004X.31.van Vliet E. A., da Costa Araújo S., Redeker S. et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy // Brain. 2007. Vol. 130, Pt 2. P. 521-534. DOI: 10.1093/brain/awl318.32.Kim S. Y., Buckwalter M., Soreq H. et al. Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis // Epilepsia. 2012. Vol. 53, Suppl 6(0 6). P. 37-44. DOI: 10.1111/j.1528-1167.2012.03701.x33.Wang X., Xuan W., Zhu Z. Y. et al. The evolving role of neuro-immune interaction in brain repair after cerebral ischemic stroke // CNS Neurosci. Ther. 2018. Vol. 24, N 12. P. 1100-1114. DOI: 10.1111/cns.13077.34.Цыганова Т. Н., Прокопов А. Ф. Научные основы использования метода гипо-гиперокситерапии в практике митохондриальной медицины // Физиотерапевт. 2016. № 3. С. 15-22.35.Thibodeaux K., Speyrer M., Raza A. et al. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series // J. Wound Care. 2020. Vol. 29(Sup5a). P. S4-S8. DOI: 10.12968/jowc.2020.29.Sup5a.S4.36.Wu J. H., Batist G. Glutathione and glutathione analogues; therapeutic potentials // Biochim. Biophys. Acta. 2013. Vol. 1830, N 5. P. 3350-3353. DOI: 10.1016/j.bbagen.2012.11.016.37.Habtemariam S., Daglia M., Sureda A. et al. Melatonin and respiratory diseases: a review // Curr. Top. Med. Chem. 2017. Vol. 17, N 4. P. 467-488. DOI: 10.2174/1568026616666160824120338.38.Wu X., Ji H., Wang Y. et al. Melatonin alleviates radiation-induced lung injury via regulation of miR-30e/NLRP3 axis // Oxid. Med. Cell Longev. 2019. Vol. 2019. P. 4087298. DOI: 10.1155/2019/4087298.